

## SELECTED PUBLICATIONS (115 Publications)

- Scanlon K.J.**, Newman, E.M., Lu Y., and Priest D.G. Biochemical basis for cisplatin and 5-Fura synergism in human ovarian carcinoma cells. **Proc. Nat'l. Acad. Sci. (USA)** **83:8923-8925, 1986.**
- Scanlon, K.J.** and Kashani-Sabet, M. Elevated expression of dTMP synthase cycle genes in cisplatin-resistant human ovarian carcinoma cells. **Proc. Nat'l. Acad. Sci (USA)** **85:650-653, 1988.**
- Lu, Y., Han, J., and **Scanlon, K.J.** Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. **J. Biol. Chem.** **263:4891-4894, 1988.**
- Kashani-Sabet, M., Rossi, J.J., Lu, Y., Ma, J.X., Chen, J., Miyachi, H., and **Scanlon, K.J.** Detection of drug resistance in human tumors by PCR assay. **Cancer Research** **48:5775-5778, 1988.**
- Scanlon, K.J.**, Kashani-Sabet, M., and Sowers, L. Overexpression of DNA replication and repair enzymes in cisplatin-resistant cells and circumvention by AZT. **Cancer Comm.** **1:269-275, 1989.**
- Scanlon, K.J.**, Funato, T., Pezeshki, B., Tone, T., and Sowers, L.C. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. **Cancer Comm.** **2:339-344, 1990.**
- Kashani-Sabet, M., Wang, W., and **Scanlon, K.J.** Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. **J. Biol. Chem.** **263:11285-11288, 1990.**
- Scanlon, K.J.**, Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J., and Kashani-Sabet, M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. **Proc. Nat'l. Acad. Sci. (USA)** **88:10592-10595, 1991.**
- Kashani-Sabet, M., Funato, T., Tone, T., Jiao, L., Wang, W., Yoshida, E. Wu, A.M., Moreno, J.G., Traweek, S.T., Ahlering, T.E., and **Scanlon, K.J.** Reversal of the malignant phenotype by an anti-ras ribozymes. **Antisense Res. & Dev.** **2:3-15, 1992.**
- Kashani-Sabet, M., Funato, T., Florenes, V.A., Fodstad, O., and **Scanlon, K.J.** Suppression of the neoplastic phenotype *in vivo* by an anti-ras ribozyme. **Cancer Research** **54:900-902, 1994.**
- Scanlon, K.J.**, Ishida, H., and Kashani-Sabet, M. Reversal of the multi-drug resistant phenotype by a fos ribozyme. **Proc. Nat'l. Acad. Sci. (USA)** **91:11123-11127, 1994.**
- Feng, M., Cabrera, G., **Scanlon, K.J.**, and Curiel, D. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. **Cancer Research** **55:2024-228, 1995.**
- Scanlon, K.J.**, Ohta, Y., Ishida, H., Kijima, H., Ohkawa, T., Kaminiski, A., Tsai, J., Hornig, G. and Kashani-Sabet, M. Oligonucleotide-mediated modulation of mammalian gene expression. **FASEB Jour.** **9:1288-1296, 1995.**
- Ohta, Y., Kijima, H., Ohkawa, T., Kashani-Sabet, M., and **Scanlon, K.J.** Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. **J. Invest. Derm.** **106:275-280, 1996.**
- Maelandsmo, G.M., Hovig, E., Engebraaten, O., Skrede, M., Florenes, V.A., Myklebost, O., Grigorian, M., Lukanidin, E., **Scanlon, K.J.**, and Fodstad, O. Reversal of the *in vivo* metastatic phenotype of human tumor cells by an anti-CAPL (*mts1*) ribozyme. **Cancer Res.** **56:5490-5498, 1996.**
- Irie, A., Anderegg, B., Kashani-Sabet, M., Ohkawa, T., Suzuki, T., Halks-Miller, M., Curiel, D., and **Scanlon, K.J.** Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. **Antisense & Nucleic Acid Drug Dev.** **9:341-349, 1999.**
- Tsuchida, T., Kijima, H., Hori, S., Oshika, Y., Tokunaga, T., Kawai, K., Yamazaki, H., Ueyama, Y., **Scanlon, K.J.**, Tamaoki, N., and Nakamura, Adenovirus-mediated anti-Kras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. **Gene Therapy**, **7:373-383, 2000.**
- Suzuki, T., Anderegg, B., Ohkawa, T., Irie, A., Engebraaten, O., Halks-Miller, M., Holm, PS., Curiel, DT., Kashani-Sabet, M., and **Scanlon, K.J.** Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits *in vivo* growth of breast cancer cells. **Gene Therapy**, **7:241-248, 2000.**
- Zhang, Y-A, Nemunaitis J, **Scanlon, K.J.**, and Tong, AW. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. **Gene Therapy**, **7:2041-2050, 2000.**
- Iida, T., Kijima, H., Urata, Y., Goto, S., Ihara, Y., Oka, M., Kohno, S., **Scanlon, K.J.**, Kondo, T. Hammerhead ribozyme against  $\gamma$ -glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. **Cancer Gene Therapy**, **8:803-814, 2001.**
- Nagata, J., Kijima, H., Hatanaka, H., Asai, S., Miyachi, H., Takagi, A., Miwa, T., Mine, T., Yamazaki, H., Nakamura, M., Kondo, T., **Scanlon, K.J.**, Ueyama, Y. Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. **Biochemical and Biophysical Research Communications**, **286:406-413, 2001.**
- Hatanaka, H., Abe, Y., Naruke, M., Asai, S., Miyachi, H., Kawakami, T., Nagata, J., Kamochi, J., Kijima, H., Yamazaki, H., **Scanlon, K.J.**, Ueyama, Y., Nakamura, M. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme. **Anticancer Research**, **21:879-886, 2001.**
- Nagata, J., Kijima, H., Hatanaka, H., Asai, S., Miyachi, H., Abe, Y., Yamazaki, H., Nakamura, M., Watanabe, N., Mine, T., Kondo, T., **Scanlon, K.J.**, Ueyama, Y., Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. **Int. J Oncol.**, **21:1021-1026, 2002.**

### Invited Papers

- Scanlon, K.J.** and Kashani-Sabet, M. Ribozymes as therapeutic agents: are we getting closer? **Jour. of the NCI**, **90:8, 1998.**
- Kashani-Sabet, M. and **Scanlon, K.J.** Antisense and Ribozyme Therapy, **Cancer Handbook**, Macmillan Publisher, London, England Chapter **91, 2001.**
- Scanlon, K.J.** and Kashani-Sabet, M. Ribozymes and Antisense. **Encyclopedia of the Human Genome**, Nature Publishing Group, Article #762, 2002.
- Scanlon, K. J.** Cancer Gene Therapy: Challenges and Opportunities. **Anticancer Res.**, **24: 501-4, 2004**
- Scanlon, K. J.** Anti-Genes: siRNA, Ribozymes & Antisense. **Curr. Pharma. Biotechnology**, **5:in press, 2004.**